within
month
detect
influenza
viru
north
america
australia
experienc
rapid
spread
viru
within
commun
burden
diseas
hospit
particular
intens
care
unit
icu
consider
epidemiolog
anim
model
data
suggest
may
virul
season
strain
influenza
procalcitonin
novel
biomark
potenti
use
diagnost
prognost
purpos
normal
physiolog
condit
releas
thyroid
gland
assist
mainten
calcium
homeostasi
contrast
releas
lipopolysaccharid
cytokin
eg
tnf
alpha
bacteri
infect
upregul
express
varieti
site
includ
liver
kidney
monocyt
compar
clinic
featur
radiolog
find
tradit
marker
white
cell
count
wcc
creactiv
protein
crp
procalcitonin
measur
may
better
mean
distinguish
viral
bacteri
infect
henc
need
antibiot
therapi
howev
respiratori
set
studi
date
focus
children
less
sever
diseas
includ
patient
influenza
studi
aim
examin
whether
admiss
adult
icu
procalcitonin
level
andor
crp
discrimin
influenza
infect
communityacquir
pneumonia
bacteri
origin
studi
conduct
icu
tertiari
hospit
western
australia
studi
design
retrospect
observ
studi
investig
carri
part
routin
clinic
manag
patient
patient
identifi
ethic
approv
requir
patient
admit
icu
may
septemb
communityacquir
pneumonia
consid
studi
comparison
limit
microbiolog
confirm
aetiolog
posit
viral
cultur
polymeras
chain
reaction
perform
respiratori
specimen
bacteri
infect
cultur
recognis
pathogen
blood
stream
andor
lower
respiratori
tract
specimen
seroconvers
mycoplasmachlamydophilalegionella
patient
mix
bacteri
infect
group
togeth
bacteri
infect
demograph
clinic
data
first
h
admiss
icu
collect
exist
databas
procalcitonin
crp
measur
routin
perform
least
twice
weekli
procalcitonin
measur
perform
use
vida
brahm
enzymelink
fluoresc
assay
biomerieux
franc
interpret
cutoff
bacteri
sepsi
consid
greater
ngml
studi
crp
measur
perform
use
architect
latexenhanc
immunoturbidimetr
assay
abbott
diagnost
abbott
park
il
studi
period
empir
manag
patient
admit
icu
suspect
pneumonia
bacteri
viral
includ
antibacteri
therapi
fisher
exact
test
use
compar
proport
categor
variabl
continu
variabl
student
test
mannwhitney
u
test
use
compar
parametr
nonparametr
data
respect
receiveroper
characterist
roc
curv
analysi
perform
use
graphpad
prism
version
studi
period
patient
consid
analysi
one
patient
infect
mix
infect
blood
cultur
posit
streptococcu
pneumonia
separ
patient
accord
aetiolog
creat
two
group
comparison
patient
infect
group
bacterialmix
infect
bacterialmix
group
tabl
three
patient
within
group
remain
icu
comparison
bacterialmix
group
reveal
group
significantli
like
bilater
chest
xray
infiltr
lower
apach
score
lower
median
white
cell
count
prolong
length
stay
icu
follow
admiss
icu
median
day
level
first
measur
day
interquartil
rang
iqr
procalcitonin
day
iqr
crp
figur
b
demonstr
initi
procalcitonin
crp
valu
two
group
admiss
icu
group
median
valu
procalcitonin
vs
ngml
p
crp
vs
mgl
p
significantli
lower
bacterialmix
group
cutoff
ngml
procalcitonin
best
identifi
patient
bacterialmix
infect
sensit
specif
neg
predict
valu
npv
posit
predict
valu
ppv
crp
cutoff
mgl
best
identifi
patient
bacterialmix
infect
sensit
specif
npv
ppv
figur
present
correspond
roc
curv
procalcitonin
crp
area
roc
curv
procalcitonin
confid
interv
ci
compar
crp
ci
use
combin
procalcitonin
level
ngml
crp
mgl
optim
sensit
specif
npv
ppv
detect
patient
bacterialmix
infect
two
patient
within
group
die
higher
mean
procalcitonin
valu
admiss
icu
compar
surviv
vs
ngml
p
experi
use
biomark
diagnost
prognost
adjunct
influenza
pandem
lack
studi
describ
abil
procalcitonin
crp
discrimin
viral
bacteri
infect
includ
patient
influenza
sever
diseas
limit
applic
scenario
current
face
intensivist
anim
model
use
avian
recombin
viru
shown
dysregul
cytokin
product
featur
sever
infect
virul
strain
influenza
although
interplay
cytokin
product
procalcitonin
complex
find
suggest
increas
express
biomark
appear
occur
despit
signific
viral
associ
pneumon
occas
carditi
myositi
interestingli
small
case
seri
singapor
patient
ventil
sever
sar
coronaviru
infect
demonstr
procalcitonin
level
ngml
compar
result
studi
diagnost
util
procalcitonin
compar
crp
disput
recent
metaanalysi
conclud
procalcitonin
accur
crp
distinct
viral
bacteri
infect
howev
perform
may
vari
depend
microbi
factor
sever
diseas
clinic
syndrom
cutoff
use
studi
set
appropri
cutoff
appli
marker
potenti
use
neg
predict
valu
howev
lower
specif
procalcitonin
favour
crp
identif
patient
bacterialmix
infect
contrari
previou
attempt
use
combin
biomark
improv
differenti
viral
bacteri
pneumonia
found
combin
procalcitonin
crp
improv
distinct
two
group
data
suggest
patient
higher
procalcitonin
level
wors
prognosi
icu
set
procalcitonin
known
prognost
valu
combin
clinic
judgement
may
allow
earlier
cessat
antibiot
therapi
given
tendenc
administ
antivir
antibacteri
therapi
patient
infect
addit
studi
requir
determin
whether
low
procalcitonin
level
could
safe
use
reduc
antibiot
use
set
small
sampl
size
retrospect
natur
studi
necessit
cautiou
interpret
result
also
acknowledg
limit
studi
microbiolog
confirm
viral
bacteri
diagnosi
made
may
creat
bia
toward
two
easili
discern
group
final
assess
rel
valu
biomark
may
enhanc
knowledg
kinet
properti
known
favour
procalcitonin
crp
conclus
studi
suggest
adult
measur
procalcitonin
level
assist
discrimin
sever
lower
respiratori
tract
infect
bacteri
origin
although
less
effect
crp
low
valu
particularli
combin
low
crp
valu
suggest
bacteri
infect
either
alon
combin
influenza
unlik
combin
clinic
judgement
potenti
identifi
group
patient
antibacteri
therapi
may
withheld
